Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion type Assertion NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_head.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion evidence source_evidence_literature NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion SIO_000772 16341239 NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion wasDerivedFrom befree-20140225 NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.
- NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_assertion wasGeneratedBy ECO_0000203 NP550188.RAEPo34PUksataH3L6mBCZTIlfv3bK_25sQRj5QJ_0WMU130_provenance.